Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) FCF Margin (2020 - 2025)

Silence Therapeutics' FCF Margin history spans 6 years, with the latest figure at 50844.12% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 5073527.0% to 50844.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 11649.72%, a 1149213.0% decrease, with the full-year FY2025 number at 11149.55%, down 1099270.0% from a year prior.
  • FCF Margin hit 50844.12% in Q4 2025 for Silence Therapeutics, down from 6847.17% in the prior quarter.
  • Over the last five years, FCF Margin for SLN hit a ceiling of 0.0% in Q2 2021 and a floor of 384192.11% in Q1 2021.
  • Historically, FCF Margin has averaged 23325.87% across 5 years, with a median of 266.36% in 2022.
  • Biggest five-year swings in FCF Margin: skyrocketed 38394180bps in 2022 and later tumbled -5073527bps in 2025.
  • Tracing SLN's FCF Margin over 5 years: stood at 255.16% in 2021, then dropped by -13bps to 287.2% in 2022, then plummeted by -98bps to 569.56% in 2023, then soared by 81bps to 108.84% in 2024, then crashed by -46613bps to 50844.12% in 2025.
  • Business Quant data shows FCF Margin for SLN at 50844.12% in Q4 2025, 6847.17% in Q3 2025, and 10919.5% in Q2 2025.